Kazuhiro Takahashi, PURMX Therapeutics – Novel MicroRNA-based Medicine for Oncology | LSI Asia '25

PURMX Therapeutics is developing novel nucleic acid medicines using proprietary small RNA-based technologies designed to modulate multiple gene targets. The company’s lead candidate, MIRX002, is a microRNA-based therapy for malignant pleural mesothelioma, currently being evaluated in investigator-initiated clinical trials at Hiroshima University Hospital. PURMX has also initiated a sponsor-led trial in Japan for head and neck squamous cell carcinoma (HNSCC).